Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-center, Randomized, Parallel Group Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Insulin Tregopil (IN-105) Compared With Insulin Aspart in the Treatment of Patients With Type 2 Diabetes Mellitus on Stable Dose of Metformin and Insulin Glargine

NCT03430856 is registered in ClinicalTrials.gov with Biocon Limited as lead sponsor.

NCT NCT03430856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03430856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-center, Randomized, Parallel Group Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Insulin Tregopil (IN-105) Compared With Insulin Aspart in the Treatment of Patients With Type 2 Diabetes Mellitus on Stable Dose of Metformin and Insulin Glargine
Lead sponsor
Biocon Limited
Phase
Phase 2/3
Overall status
Completed
Start date
December 26, 2017
Completion date
February 20, 2019
Enrollment
143 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type2 diabetes mellitus